SCHEMBL22115127

SCHEMBL22115127

CP(C)(=O)c1cccc2c(-c3nc(N[C@H]4CCCNC4)ncc3C(F)(F)F)c[nH]c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 19/20 1.00
▸ CDK12 Q9NYV4 19/20 1.00
▸ CCNT1 O60563 18/20 1.00
▸ CDK9 P50750 18/20 1.00
▸ CCNE1 P24864 15/20 1.00
▸ CDK2 P24941 15/20 1.00
▸ CDK7 P50613 8/20 1.00
▸ CCNH P51946 8/20 1.00
▸ MNAT1 P51948 6/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25599168 1.00 CCNK (1.00) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24588157 1.00 CCNK (1.00) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24145818 0.92 CCNT1 (0.85) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24588204 0.92 CCNK (0.84) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL30685928 0.92 CCNK (0.84) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24839381 0.91 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24840737 0.90 CDK7 (1.00) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL24839802 0.89 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL29498413 0.87 CCNK (0.77) CCNKCDK12CCNT1CDK9CCNE1
SCHEMBL29498461 0.86 CCNK (0.76) CCNKCDK12CCNT1CDK9CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 — — EP disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 — — EP disclosed
US-20230000870-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-01-05 — — US disclosed
US-20210401859-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2021-12-30 — — US disclosed
US-10738067-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2020-08-11 — — US disclosed
US-20200190126-A1 Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2020-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000870-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, RB1, MKI67 CCNK 10/4885CDK12 29/4885CCNT1 41/4885
US-10738067-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK1, CDK17 CCNK 8/4885CDK12 30/4885CCNT1 35/4885
US-20210401859-A1 METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK4, RB1 CCNK 13/4885CDK12 32/4885CCNT1 28/4885
US-20200190126-A1 Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) CDK7, CDK1, CDK17 CCNK 8/4885CDK12 30/4885CCNT1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback